Potential conflict of interest: Dr. Yazdanpanah consults for Abbott, Bristol-Myers Squibb, Gilead, Tibotec, ViiV Healthcare, and MSD.
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach
Version of Record online: 25 FEB 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 4, pages 1471–1481, April 2014
How to Cite
Mourad, A., Deuffic-Burban, S., Ganne-Carrié, N., Renaut-Vantroys, T., Rosa, I., Bouvier, A.-M., Launoy, G., Cattan, S., Louvet, A., Dharancy, S., Trinchet, J.-C., Yazdanpanah, Y. and Mathurin, P. (2014), Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. Hepatology, 59: 1471–1481. doi: 10.1002/hep.26944
Supported by a grant (INCa_1496) from the French National Cancer Institute (INCa), the Cancer Research Association (ARC) and the French National AIDS and Viral Hepatitis Research Agency (ANRS) teamed up to launch an Integrated Research Action Programme on hepatocellular carcinoma (HCC PAIR).
- Issue online: 24 MAR 2014
- Version of Record online: 25 FEB 2014
- Accepted manuscript online: 21 NOV 2013 02:20AM EST
- Manuscript Accepted: 18 NOV 2013
- Manuscript Received: 9 JUN 2013
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.